ENTX
Price
$3.02
Change
-$0.03 (-0.98%)
Updated
Oct 22 closing price
Capitalization
522.89M
22 days until earnings call
Intraday BUY SELL Signals
LGVN
Price
$1.59
Change
+$0.16 (+11.19%)
Updated
Oct 22 closing price
Capitalization
5.07M
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ENTX vs LGVN

ENTX vs LGVN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ENTX vs. LGVN commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTX is a StrongBuy and LGVN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ENTX with price predictions
Oct 22, 2026

ENTX's RSI Indicator climbs out of oversold territory

The RSI Indicator for ENTX moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 33 of the 35 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on ENTX as a result. In 76 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for ENTX just turned positive on October 16, 2026. Looking at past instances where ENTX's MACD turned positive, the stock continued to rise in 47 of 53 cases over the following month. The odds of a continued upward trend are 89%.

ENTX moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +3.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENTX advanced for three days, in 180 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

ENTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 10-day moving average for ENTX crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for ENTX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ENTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ENTX's P/B Ratio (71.964) is slightly higher than the industry average of (2.973). P/E Ratio (-8.629) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1428.571) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for LGVN with price predictions
Oct 22, 2026

Momentum Indicator for LGVN turns negative, indicating new downward trend

LGVN saw its Momentum Indicator move below the 0 level on October 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned negative. In 90 of the 96 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LGVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for LGVN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LGVN's RSI Indicator exited the oversold zone, 34 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for LGVN just turned positive on September 30, 2026. Looking at past instances where LGVN's MACD turned positive, the stock continued to rise in 38 of 44 cases over the following month. The odds of a continued upward trend are 86%.

LGVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.487) is normal, around the industry mean (2.973). P/E Ratio (-0.159) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (13.587) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. LGVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LGVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ENTX: Fundamental Ratings
ENTX
OUTLOOK RATING
1..100
88
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
90
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ENTXLGVN
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 10 days ago
89%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ENTX: $3.05 vs. LGVN: $1.43)
Brand notoriety: ENTX and LGVN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTX: 180% vs. LGVN: 76%
Market capitalization -- ENTX: $522.89M vs. LGVN: $5.07M
ENTX [@Biotechnology] is valued at $522.89M. LGVN’s [@Biotechnology] market capitalization is $5.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTX’s FA Score shows that 0 FA rating(s) are green while LGVN’s FA Score has 0 green FA rating(s).

  • ENTX’s FA Score: 0 green, 5 red.
  • LGVN’s FA Score: 0 green, 5 red.
According to our system of comparison, ENTX is a better buy in the long-term than LGVN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTX’s TA Score shows that 6 TA indicator(s) are bullish while LGVN’s TA Score has 4 bullish TA indicator(s).

  • ENTX’s TA Score: 6 bullish, 4 bearish.
  • LGVN’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, ENTX is a better buy in the short-term than LGVN.

Price Growth

ENTX (@Biotechnology) experienced а +22.00% price change this week, while LGVN (@Biotechnology) price change was -17.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

ENTX is expected to report earnings on Nov 13, 2026.

LGVN is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ENTX
Daily Signal:
Gain/Loss:
LGVN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ENTX and

Correlation & Price change

A.I.dvisor tells us that ENTX and JSPR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ENTX and JSPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTX
1D Price
Change %
ENTX100%
-0.98%
JSPR - ENTX
32%
Poorly correlated
-1.73%
MLTX - ENTX
30%
Poorly correlated
+15.87%
QCLS - ENTX
26%
Poorly correlated
+3.50%
NTLA - ENTX
26%
Poorly correlated
-4.21%
LGVN - ENTX
25%
Poorly correlated
+11.19%
More

LGVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, LGVN has been loosely correlated with QURE. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if LGVN jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LGVN
1D Price
Change %
LGVN100%
+11.19%
QURE - LGVN
37%
Loosely correlated
+1.85%
BIVI - LGVN
37%
Loosely correlated
+1.59%
SNGX - LGVN
36%
Loosely correlated
+0.30%
KZIA - LGVN
32%
Poorly correlated
-1.34%
AXON - LGVN
30%
Poorly correlated
+2.98%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GEN24.890.77
+3.19%
Gen Digital
BOH70.261.32
+1.91%
Bank of Hawaii Corp
MTEK0.39-0.01
-3.70%
Maris-Tech Ltd
HYLN3.10-0.17
-5.20%
Hyliion Holdings Corp
TNXP5.13-0.30
-5.52%
Tonix Pharmaceuticals Holding Corp